IP Library › Granted Patent US 9,353,187
Granted Patent B2
US 9,353,187 · App. 13/773,485 · Granted May 31, 2016

Optimized FC variants and methods for their generation

Inventors: Gregory Alan Lazar (Indianapolis, IN); Arthur J. Chirino (Camarillo, CA); Wei Dang (Pasadena, CA); John Desjarlais (Pasadena, CA); Stephen K. Doberstein (San Francisco, CA); Robert J. Hayes (Radnor, PA); Sher Bahadur Karki (Santa Monica, CA); Omid Vafa (Monrovia, CA)
Assignee: Xencor, Inc.
C07K16/32A61K39/395A61K39/3955A61K39/39566C07K16/00C07K16/22C07K16/2863C07K16/2875C07K16/2887C07K16/2893C07K16/2896C07K16/4291A61K2039/505C07K2317/21C07K2317/24C07K2317/34C07K2317/52C07K2317/72C07K2317/732C07K2317/734C07K2317/76C07K2317/77C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,353,187
App. No.
13/773,485
Granted
May 31, 2016
Kind
B2
Abstract

The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.

Claims (9)

1. A method of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) in a human comprising administering to a human a composition comprising a variant antibody of a parent antibody which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human peripheral blood mononuclear cells more effectively than the parent antibody, wherein said variant comprises a 239D substitution in the Fc region, wherein numbering is according to the EU index.

2. A method of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) in a human comprising administering to a human a composition comprising a variant antibody of a parent antibody which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human peripheral blood mononuclear cells more effectively than the parent antibody, wherein said variant comprises a 239E substitution in the Fc region, wherein numbering is according to the EU index.

3. A method according to claim 1 or 2 wherein said variant antibody is a monoclonal antibody.

4. A method according to claim 1 or 2 wherein said variant antibody is a humanized antibody.

5. A method according to claim 1 or 2 wherein said variant antibody is a chimeric antibody.

6. A method according to claim 1 or 2 wherein said antibody binds to CD19.

7. A method according to claim 1 or 2 wherein said antibody binds to IgE.

8. A method according to claim 1 or 2 wherein said parent antibody is a human IgG1.

9. A method according to claim 1 or 2 wherein said variant antibody binds to a target antigen selected from the group consisting of CD20, CD30, CD33, CD37, CD38 and CD3.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2015
From: LAZAR, GREGORY ALAN; CHIRINO, ARTHUR J.; DANG, WEI; DESJARLAIS, JOHN RUDOLPH; DOBERSTEIN, STEPHEN KOHL; HAYES, ROBERT J.; KARKI, SHER BAHADUR; VAFA, OMID
To: XENCOR, INC.
Reel/Frame 036752/0877 →
Continuity (8)
Division 13346604 · Jan 9, 2012
Division 11981822 · Oct 31, 2007
Division 10672280 · Sep 26, 2003
Provisional Application 60477839 · Jun 12, 2003
Provisional Application 60467606 · May 2, 2003
Provisional Application 60442301 · Jan 23, 2003
Provisional Application 60414433 · Sep 27, 2002
Related Publication 20130156754A1 · Jun 20, 2013